Pharmaceuticals Company Announces Results of Study For OTC Access To ED Drug

Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), commonly referred to as "Petros" or "the Company," has recently announced the results of a pivotal study aimed at enabling over-the-counter (OTC) access to STENDRA® (avanafil). This development represents a step forward in the Company’s mission to expand consumer access to medication through innovative OTC drug development programs. The primary goal of this study was to facilitate the FDA-approved OTC availability of STENDRA®, a drug traditionally used to treat erectile dysfunction. $Petros Pharmaceuticals(PTPI.US)$